First-in-class small molecule modulators of RNA
Arrakis is building a proprietary platform to enable the rational, structure-based design of orally acting small molecules that bind RNA, and so directly modulate RNA function.
CEO Michael Gilman
Advent Contact Raj Parekh
Advent founded Arrakis in 2014.
Private Companies
Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics
Press Release. Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics Collaboration Creates “Targeted RNA Degraders” by Bringing Together Amgen’s Induced Proximity Platform…
Read More
Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform
Press Release. Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform Arrakis Receives $190 Million Upfront Cash Payment…
Read More
Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA
Press Release. April 18, 2019 Michael Gilman, Ph.D., to expand role to full-time CEO to lead company to clinical stage Having established first-in-industry RNA-targeted Small Molecule (rSM) platform, Arrakis…
Read More
Arrakis Therapeutics Announces $38M Series A Financing To Target RNA with Small-Molecule Medicines And Names Michael Gilman Chairman and CEO
Press Release. Veteran management team to re-architect small molecule drug discovery to pursue new RNA targets within vast human transcriptome Waltham, Mass., February 27, 2017 – Arrakis Therapeutics, a…
Read More
